Epigenetic Versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2018 Apr 13

PMID 29643973

Citations 39

Authors

F P Fabrizio

A Sparaneo

D Trombetta

L A Muscarella

Affiliations

Soon will be listed here.

Abstract

Oxidative and electrophilic changes in cells are mainly coordinated by the KEAP1/NRF2 (Kelch-like erythroid-derived cap-n-collar homology- (ECH-) associated protein-1/nuclear factor (erythroid-derived 2)-like 2) axis. The physical interaction between these two proteins promotes the expression of several antioxidant defense genes in response to exogenous and endogenous insults. Recent studies demonstrated that KEAP1/NRF2 axis dysfunction is also strongly related to tumor progression and chemo- and radiotherapy resistance of cancer cells. In solid tumors, the KEAP1/NRF2 system is constitutively activated by the loss of or gain of functions that leads to its nuclear accumulation and enhances the transcription of many cytoprotective genes. In addition to point mutations, epigenetic abnormalities, as aberrant promoter methylation, and microRNA (miRNA) and long noncoding RNA (lncRNA) deregulation were reported as emerging mechanisms of KEAP1/NRF2 axis modulation. This review will summarize the current knowledge about the epigenetic mechanisms that deregulate the KEAP1/NRF2 cascade in solid tumors and their potential usefulness as prognostic and predictive molecular markers.

Citing Articles

KLF5 promotes esophageal squamous cell carcinoma radioresistance by targeting the Keap1-Nrf2 pathway.

Wang Y, Yang Y, Kamili A, Aishanjiang D, Liu Y Discov Oncol. 2025; 16(1):130.

PMID: 39918680 PMC: 11805730. DOI: 10.1007/s12672-025-01868-x.

Nrf2 Signaling in Renal Cell Carcinoma: A Potential Candidate for the Development of Novel Therapeutic Strategies.

Schiavoni V, Emanuelli M, Milanese G, Galosi A, Pompei V, Salvolini E Int J Mol Sci. 2025; 25(24.

PMID: 39769005 PMC: 11675435. DOI: 10.3390/ijms252413239.

How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy.

Tang Y, Chuang Y, Chang H, Juang S, Yen G, Chang J J Food Drug Anal. 2024; 31(3):387-407.

PMID: 39666284 PMC: 10629913. DOI: 10.38212/2224-6614.3463.

Effects of Silencing on NRF2 and NOTCH Pathways in SCLC Cell Lines.

Fabrizio F, Sparaneo A, Gorgoglione G, Battista P, Centra F, Delli Muti F Cancers (Basel). 2024; 16(10).

PMID: 38791966 PMC: 11120002. DOI: 10.3390/cancers16101885.

Keap1-Nrf2 pathway: a key mechanism in the occurrence and development of cancer.

Chen F, Xiao M, Hu S, Wang M Front Oncol. 2024; 14:1381467.

PMID: 38634043 PMC: 11021590. DOI: 10.3389/fonc.2024.1381467.

References

Ayers D, Baron B, Hunter T . miRNA Influences in NRF2 Pathway Interactions within Cancer Models. J Nucleic Acids. 2015; 2015:143636. PMC: 4546755. DOI: 10.1155/2015/143636. View

Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K, Inazawa J . The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer Res. 2013; 12(1):58-68. DOI: 10.1158/1541-7786.MCR-13-0246-T. View

Itoh K, Ye P, Matsumiya T, Tanji K, Ozaki T . Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria. J Clin Biochem Nutr. 2015; 56(2):91-7. PMC: 4345178. DOI: 10.3164/jcbn.14-134. View

Cescon D, She D, Sakashita S, Zhu C, Pintilie M, Shepherd F . NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma. Clin Cancer Res. 2015; 21(11):2499-505. DOI: 10.1158/1078-0432.CCR-14-2206. View

Muscarella L, Barbano R, DAngelo V, Copetti M, Coco M, Balsamo T . Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics. 2010; 6(3):317-25. PMC: 3092680. DOI: 10.4161/epi.6.3.14408. View

Zucman-Rossi J, Villanueva A, Nault J, Llovet J . Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology. 2015; 149(5):1226-1239.e4. DOI: 10.1053/j.gastro.2015.05.061. View

Yang M, Yao Y, Eades G, Zhang Y, Zhou Q . MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res Treat. 2011; 129(3):983-91. PMC: 3752913. DOI: 10.1007/s10549-011-1604-1. View

Liu M, Hu C, Xu Q, Chen L, Ma K, Xu N . Methylseleninic acid activates Keap1/Nrf2 pathway via up-regulating miR-200a in human oesophageal squamous cell carcinoma cells. Biosci Rep. 2015; 35(5). PMC: 4613709. DOI: 10.1042/BSR20150092. View

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

10.

Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J . Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer. 2012; 12:66. PMC: 3296656. DOI: 10.1186/1471-2407-12-66. View

11.

Chien M, Lee W, Hsieh F, Li C, Cheng T, Wang M . Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein. Clin Cancer Res. 2015; 21(20):4719-32. DOI: 10.1158/1078-0432.CCR-14-2880. View

12.

Schulze K, Imbeaud S, Letouze E, Alexandrov L, Calderaro J, Rebouissou S . Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47(5):505-511. PMC: 4587544. DOI: 10.1038/ng.3252. View

13.

Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R . CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res. 2013; 73(7):2044-51. DOI: 10.1158/0008-5472.CAN-12-3227. View

14.

Sun X, Liu D, Xue Y, Hu X . Enforced miR-144-3p Expression as a Non-Invasive Biomarker for the Acute Myeloid Leukemia Patients Mainly by Targeting NRF2. Clin Lab. 2017; 63(4):679-687. DOI: 10.7754/Clin.Lab.2016.161116. View

15.

Lister A, Nedjadi T, Kitteringham N, Campbell F, Costello E, Lloyd B . Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer. 2011; 10:37. PMC: 3098205. DOI: 10.1186/1476-4598-10-37. View

16.

Li S, Chen T, Zhong Z, Wang Y, Li Y, Zhao X . microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep. 2012; 5(4):949-54. PMC: 3493052. DOI: 10.3892/mmr.2012.779. View

17.

Guo D, Wu B, Yan J, Li X, Sun H, Zhou D . A possible gene silencing mechanism: hypermethylation of the Keap1 promoter abrogates binding of the transcription factor Sp1 in lung cancer cells. Biochem Biophys Res Commun. 2012; 428(1):80-5. DOI: 10.1016/j.bbrc.2012.10.010. View

18.

Wang X, Hayes J, Wolf C . Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res. 2006; 66(22):10983-94. DOI: 10.1158/0008-5472.CAN-06-2298. View

19.

Tian H, Zhang B, Di J, Jiang G, Chen F, Li H . Keap1: one stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL. Cancer Lett. 2012; 325(1):26-34. DOI: 10.1016/j.canlet.2012.06.007. View

20.

Khor T, Fuentes F, Shu L, Paredes-Gonzalez X, Yang A, Liu Y . Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. Cancer Prev Res (Phila). 2014; 7(12):1186-97. PMC: 4256109. DOI: 10.1158/1940-6207.CAPR-14-0127. View